Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive CYP2D6 genotyping improves phenotype classification and highlights methodological pitfalls in tamoxifen-treated breast cancer.

BMC cancer - 1 Jul 2026

Alkebbeh Linda, Berndt Anne, Oberkanins Christian, Kenj Mazen, Kriegshäuser Gernot, Youssef Lama A

Abstract excerpt

BACKGROUND: The clinical utility of CYP2D6 genotyping in predicting tamoxifen outcomes remains controversial, partly due to incomplete allele coverage and limited assessment of copy number variation (CNV). We aimed to expand CYP2D6 genetic profiling in Syrian breast cancer patients and to reassess phenotype classification and its clinical relevance. METHODS: In this retrospective cohort of estrogen...

Read the complete abstract on PubMed

Topics

Humans
Cytochrome P-450 CYP2D6
Female
Tamoxifen
Breast Neoplasms
Phenotype

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Genotype

DNA Copy Number Variations

Antineoplastic Agents, Hormonal

Retrospective Studies

Middle Aged

Adult

Disease-Free Survival

High-Throughput Nucleotide Sequencing

Aged

Source

Open in PubMed Open full text

Identifiers

PMID: 42380819
DOI: 10.1186/s12885-026-16440-1
PMCID: PMC13587297

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 16 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive CYP2D6 genotyping improves phenotype classification and highlights methodological pitfalls in tamoxifen-treated breast cancer.PMID 42380819Read ↗

Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients?Semantic proximity Read ↗

CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.Semantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.Semantic proximity Read ↗

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.Semantic proximity Read ↗

CYP2D6 Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis.Semantic proximity Read ↗

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

CYP2D6*11 and challenges in clinical genotyping of the highly polymorphic CYP2D6 gene.Semantic proximity Read ↗

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.